Show simple item record

dc.contributor.authorDa Pieve, C
dc.contributor.authorCosta Braga, M
dc.contributor.authorTurton, DR
dc.contributor.authorValla, FA
dc.contributor.authorCakmak, P
dc.contributor.authorPlate, K-H
dc.contributor.authorKramer-Marek, G
dc.date.accessioned2022-04-13T09:18:36Z
dc.date.available2022-04-13T09:18:36Z
dc.date.issued2022-01-20
dc.identifier.citationMolecules (Basel, Switzerland), 2022, 27 (3)en
dc.identifier.issn1420-3049
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/5082
dc.identifier.eissn1420-3049en_US
dc.identifier.eissn1420-3049
dc.identifier.doi10.3390/molecules27030675en_US
dc.identifier.doi10.3390/molecules27030675
dc.description.abstractA large number of applications for fibroblast activation protein inhibitors (FAPI)-based PET agents have been evaluated in conditions ranging from cancer to non-malignant diseases such as myocardial infarction. In particular, <sup>68</sup>Ga-FAPI-46 was reported to have a high specificity and affinity for FAP-expressing cells, a fast and high accumulation in tumor lesions/injuries together with a fast body clearance when investigated in vivo. Due to the increasing interest in the use of the agent both preclinically and clinically, we developed an automated synthesis for the production of <sup>68</sup>Ga-FAPI-46 on a Trasis AiO platform. The new synthetic procedure, which included the processing of the generator eluate using a strong cation exchange resin and a final purification step through an HLB followed by a QMA cartridge, yielded <sup>68</sup>Ga-FAPI-46 with high radiochemical purity (>98%) and apparent molar activity (271.1 ± 105.6 MBq/nmol). Additionally, the in vitro and in vivo properties of the product were assessed on glioblastoma cells and mouse model. Although developed for the preparation of <sup>68</sup>Ga-FAPI-46 for preclinical use, our method can be adapted for clinical production as a reliable alternative to the manual (i.e., cold kit) or modular systems preparations already described in the literature.en_US
dc.formatElectronicen_US
dc.languageengen_US
dc.language.isoengen
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/en
dc.subjectTumor Cells, Cultureden_US
dc.subjectAnimalsen_US
dc.subjectHumansen_US
dc.subjectMiceen_US
dc.subjectMice, Nudeen_US
dc.subjectGlioblastomaen_US
dc.subjectQuinolinesen_US
dc.subjectRadiopharmaceuticalsen_US
dc.subjectXenograft Model Antitumor Assaysen_US
dc.subjectApoptosisen_US
dc.subjectCell Proliferationen_US
dc.subjectRadiochemistryen_US
dc.subjectFemaleen_US
dc.subjectPositron Emission Tomography Computed Tomographyen_US
dc.titleNew Fully Automated Preparation of High Apparent Molar Activity <sup>68</sup>Ga-FAPI-46 on a Trasis AiO Platform.en
dc.typeJournal Article
dcterms.dateAccepted2022-01-17
rioxxterms.versionVoRen
rioxxterms.versionofrecord10.3390/molecules27030675en
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0en
rioxxterms.licenseref.startdate2022-01-20
dc.relation.isPartOfMolecules (Basel, Switzerland)en_US
pubs.issue3en_US
pubs.notesNot knownen_US
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Preclinical Molecular Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Preclinical Molecular Imaging
pubs.publication-statusPublisheden_US
pubs.volume27en_US
pubs.embargo.termsNot knownen_US
icr.researchteamPreclinical Molecular Imaging
dc.contributor.icrauthorKramer-Marek, Gabrielaen_US


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

http://creativecommons.org/licenses/by/4.0/
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by/4.0/